Cargando…
Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report
BACKGROUND: Approximately 10–25% of patients with small cell lung cancer (SCLC) have brain metastases at the time of diagnosis. Radiotherapy is a common treatment for brain metastases, but the relapse rates are high. Accumulating evidence suggests that immunotherapy may have a better therapeutic eff...
Autores principales: | Huang, Fengxiang, Tang, Jiaqi, Lou, Jiaojiao, Wang, Qilong, Ma, Kai, Qiao, Ruiping, Si, Jiming, Kang, Yan, Chen, Hongjie, Mei, Jingjing, Wang, Huanqin, Liu, Yuanhua, Miao, Lijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552078/ https://www.ncbi.nlm.nih.gov/pubmed/36237231 http://dx.doi.org/10.21037/tcr-22-666 |
Ejemplares similares
-
Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022) -
Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
por: Ma, Kai, et al.
Publicado: (2022) -
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023) -
Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022) -
Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023)